The Conversation (0)
Dynasil Corporation of America today announced that it has joined with Cook Biotech in order to advance the Xcede patch through its first human trials.
Dynasil Corporation of America (NASDAQ:DYSL) today announced that it has joined with Cook Biotech in order to advance the Xcede patch through its first human trials.
According to the press release:
The Xcede Patch is intended to be used during surgical procedures to stop bleeding (hemostasis). Preclinical testing to date indicates this product promotes hemostasis within 60 seconds, a time that is faster than currently approved hemostatic patches, which take approximately three minutes to stop bleeding.
Dynasil’s CEO, Peter Sulick, said the following:
“We are very thankful for the ongoing support of our development partner, Cook Biotech Inc. CBI has agreed to provide yet another level of support for this extraordinary product, one component of which is CBI’s core technology. Once in commercial production, we believe the product will greatly improve operation room efficiencies and patient outcomes.”